HER-2/neu mediated down-regulation of MHC class i antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice

Cancer Immunology, Immunotherapy

Volumn 58, Issue 5, 2009, Pages 653-664

  Vertuani, Simona ^a,f   Triulzi, Chiara ^a   Roos, Anna Karin ^a   Charo, Jehad ^b   Norell, Håkan ^c   Lemonnier, François ^d   Pisa, Pavel ^a   Seliger, Barbara ^e   Kiessling, Rolf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d INSTITUT PASTEUR   (France)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antigen processing; DNA vaccine; HER 2; MHC class I

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL EXPERIMENT; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; BASE SEQUENCE; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; GENES, ERBB-2; GENES, MHC CLASS I; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINES, DNA;

EID: 61349186956     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0587-1     Document Type: Article

References (34)

1. CN Baxevanis NN Sotiriadou AD Gritzapis PA Sotiropoulou SA Perez NT Cacoullos M Papamichail 2006 Immunogenic HER-2/neu peptides as tumor vaccines Cancer Immunol Immunother 1 85 95
2. P Brossart G Stuhler T Flad S Stevanovic HG Rammensee L Kanz W Brugger 1998 Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes Cancer Res 4 732 736
3. A Choudhury J Charo SK Parapuram RC Hunt DM Hunt B Seliger R Kiessling 2004 Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines Int J Cancer 1 71 77
4. C Cuadros AL Dominguez PL Lollini M Croft RS Mittler P Borgstrom J Lustgarten 2005 Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice Int J Cancer 6 934 943
5. M Del Val HJ Schlicht T Ruppert MJ Reddehase UH Koszinowski 1991 Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein Cell 6 1145 1153
6. ML Disis V Goodell K Schiffman KL Knutson 2004 Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients J Clin Immunol 5 571 578
7. B Fisk TL Blevins JT Wharton CG Ioannides 1995 Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines J Exp Med 6 2109 2117
8. AD Gritzapis LG Mahaira SA Perez NT Cacoullos M Papamichail CN Baxevanis 2006 Vaccination with Human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo Cancer Res 10 5452 5460
9. K Haupt M Roggendorf K Mann 2002 The potential of DNA vaccination against tumor-associated antigens for antitumor therapy Exp Biol Med (Maywood) 4 227 237
10. F Herrmann HA Lehr I Drexler G Sutter J Hengstler U Wollscheid B Seliger 2004 HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway Cancer Res 1 215 220
11. S Horiguchi M Petersson T Nakazawa M Kanda AH Zea AC Ochoa R Kiessling 1999 Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells Cancer Res 12 2950 2956
12. BL Kaplan H Norell GG Callender T Ohlum R Kiessling MI Nishimura 2006 Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells Cancer Immunol Immunother 6 653 662
13. I Kawashima SJ Hudson V Tsai S Southwood K Takesako E Appella A Sette E Celis 1998 The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors Hum Immunol 1 1 14
14. Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, Seliger B (2002) Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 101-144
15. KL Knutson K Schiffman ML Disis 2001 Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients J Clin Invest 4 477 484
16. K Kono E Halapi C Hising M Petersson E Gerdin F Vanky R Kiessling 1997 Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression Int J Cancer 1 112 119
17. Leifert JA, Rodriguez-Carreno MP, Rodriguez F, Whitton JL (2004) Targeting plasmid-encoded proteins to the antigen presentation pathways. Immunol Rev 40-53
18. JA Lindencrona S Preiss T Kammertoens T Schuler M Piechocki WZ Wei B Seliger T Blankenstein R Kiessling 2004 CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells Int J Cancer 2 259 264
19. PL Lollini G Nicoletti L Landuzzi C De Giovanni I Rossi E Di Carlo P Musiani WJ Muller P Nanni 1998 Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice Int J Cancer 6 937 941
20. J Lustgarten AL Dominguez C Cuadros 2004 The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity Eur J Immunol 3 752 761
21. S Pascolo N Bervas JM Ure AG Smith FA Lemonnier B Perarnau 1997 HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2 m) HLA-A2.1 monochain transgenic H-2Db beta2 m double knockout mice J Exp Med 12 2043 2051
22. GE Peoples JM Gurney MT Hueman MM Woll GB Ryan CE Storrer C Fisher CD Shriver CG Ioannides S Ponniah 2005 Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients J Clin Oncol 30 7536 7545
23. GE Peoples JP Holmes MT Hueman EA Mittendorf A Amin S Khoo ZA Dehqanzada JM Gurney MM Woll GB Ryan CE Storrer D Craig CG Ioannides S Ponniah 2008 Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Clin Cancer Res 3 797 803
24. MP Piechocki YS Ho S Pilon WZ Wei 2003 Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines J Immunol 11 5787 5794
25. E Quaglino M Iezzi C Mastini A Amici F Pericle E Di Carlo SM Pupa C De Giovanni M Spadaro C Curcio PL Lollini P Musiani G Forni F Cavallo 2004 Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice Cancer Res 8 2858 2864
26. F Rodriguez LL An S Harkins J Zhang M Yokoyama G Widera JT Fuller C Kincaid IL Campbell JL Whitton 1998 DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination J Virol 6 5174 5181
27. Y Rongcun F Salazar-Onfray J Charo KJ Malmberg K Evrin H Maes K Kono C Hising M Petersson O Larsson L Lan E Appella A Sette E Celis R Kiessling 1999 Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas J Immunol 2 1037 1044
28. AK Roos S Moreno C Leder M Pavlenko A King P Pisa 2006 Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation Mol Ther 2 320 327
29. A Scardino M Alimandi P Correale SG Smith R Bei H Firat MG Cusi O Faure S Graf-Dubois G Cencioni J Marrocco S Chouaib FA Lemonnier AM Jackson K Kosmatopoulos 2007 A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge Cancer Res 14 7028 7036
30. B Seliger Y Rongcun D Atkins S Hammers C Huber S Storkel R Kiessling 2000 HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes Int J Cancer 3 349 359
31. S Torsteinsdottir MG Masucci B Ehlin-Henriksson C Brautbar H Ben Bassat G Klein E Klein 1986 Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity Proc Natl Acad Sci USA 15 5620 5624
32. TM Tran P Ivanyi I Hilgert T Brdicka M Pla B Breur M Flieger E Ivaskova V Horejsi 2001 The epitope recognized by pan-HLA class I-reactive monoclonal antibody W6/32 and its relationship to unusual stability of the HLA-B27/beta2-microglobulin complex Immunogenetics 6 440 446
33. WZ Wei WP Shi A Galy D Lichlyter S Hernandez B Groner L Heilbrun RF Jones 1999 Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA Int J Cancer 5 748 754
34. TZ Zaks SA Rosenberg 1998 Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors Cancer Res 21 4902 4908